Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Melissa K. Bennett"'
Autor:
Melissa K. Bennett, Manjun Li, Melinda N. Tea, Melissa R. Pitman, John Toubia, Paul P.-S. Wang, Dovile Anderson, Darren J. Creek, Robert Z. Orlowski, Briony L. Gliddon, Jason A. Powell, Craig T. Wallington-Beddoe, Stuart M. Pitson
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 24, Iss 1, Pp 1-11 (2022)
The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival. However, whilst bortezomib elicits initial responses in many myeloma patients, this haematological mal
Externí odkaz:
https://doaj.org/article/f5e0bdd9d3004cfdbf70bbe296a47fe3
Autor:
Briony L. Gliddon, Craig T. Wallington-Beddoe, Manjun Li, Darren J. Creek, Melissa R. Pitman, Melinda N. Tea, Paul Wang, Dovile Anderson, John Toubia, Melissa K. Bennett, Robert Z. Orlowski, Stuart M. Pitson, Jason A. Powell
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 24, Iss 1, Pp 1-11 (2022)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Refereed/Peer-reviewed The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival. However, whilst bortezomib elicits initial responses in many myeloma patients,
Publikováno v:
Resistance to Targeted Anti-Cancer Therapeutics ISBN: 9783030734398
The first clinically available proteasome inhibitor (PI) bortezomib was trialed in multiple myeloma (MM) approximately two decades ago and has since become a mainstay of myeloma therapy, significantly enhancing the overall survival of patients. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a56aa2144e3015a13dfc761b1a1d6e4
https://doi.org/10.1007/978-3-030-73440-4_4
https://doi.org/10.1007/978-3-030-73440-4_4
Autor:
Craig T. Wallington-Beddoe, Melissa R. Pitman, Melissa K. Bennett, Andrew C.W. Zannettino, Paul A.B. Moretti, Julia R. Zebol, Duncan R. Hewett, Kate Vandyke, Stuart M. Pitson, Lorena T. Davies
Publikováno v:
Oncotarget
// Craig T. Wallington-Beddoe 1,2,3 , Melissa K. Bennett 1,2,3 , Kate Vandyke 2,3,4 , Lorena Davies 1,2 , Julia R. Zebol 1,2 , Paul A.B. Moretti 1,2 , Melissa R. Pitman 1,2 , Duncan R. Hewett 3,4 , Andrew C.W. Zannettino 1,2,3,4,* and Stuart M. Pitso
Publikováno v:
Biochimica et biophysica acta. Molecular and cell biology of lipids. 1864(10)
The unfolded protein response (UPR) is a response by the endoplasmic reticulum to stress, classically caused by any disruption to cell homeostasis that results in an accumulation in unfolded proteins. However, there is an increasing body of research
Autor:
John Toubia, Craig T. Wallington-Beddoe, Melinda N. Tea, Briony L. Gliddon, Melissa K. Bennett, Robert Z. Orlowski, Stuart M. Pitson
Publikováno v:
Experimental Hematology. 76:S58
Multiple myeloma, a haematological malignancy of the plasma cell, is still largely incurable. The introduction of proteasome inhibitors such as bortezomib has significantly improved patient survival, however bortezomib resistance is still a major hur